Jazz Pharmaceuticals acquires Actio Biosciences for $820 million

September 15, 2026 9:01 AM

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has completed its acquisition of privately-held Actio Biosciences, Inc. for $820 million upfront, making Actio ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found